Clinical Edge Journal Scan

Young women with postpartum breast cancer have worst survival


 

Key clinical point: A breast cancer (BC) diagnosis within 5 years of childbirth (postpartum BC [PPBC]) was associated with worse prognosis than no childbirth prior to diagnosis (nulliparous BC), with the association being strongest in young women diagnosed at the age of <35 years and in those with stage I disease.

Major finding: Women diagnosed with nulliparous BC vs. PPBC at age of <45 years had better overall survival (hazard ratio [HR] 0.61; 95% CI 0.42-0.87), with the difference being more pronounced in women with stage I tumors (HR 0.30; 95% CI 0.11-0.79) and in women diagnosed at the age of ≤35 years (HR 0.44; 95% CI 0.23-0.84).

Study details: The study evaluated a pooled dataset of 2519 women diagnosed with BC at the age of ≥18 years.

Disclosures: This study was funded by grants from the University of Colorado Cancer Center, National Institutes of Health, and other sources. The authors declared no conflict of interests.

Source: Shagisultanova E et al. Overall survival is the lowest among young women with postpartum breast cancer. Eur J Cancer. 2022;168:119-127 (May 4). Doi: 10.1016/j.ejca.2022.03.014

Recommended Reading

Twenty years and counting: Tamoxifen’s lasting improvement in breast cancer
MDedge Hematology and Oncology
Study shows link between dairy consumption and cancer
MDedge Hematology and Oncology
Mastectomy may not be necessary for young breast cancer patients
MDedge Hematology and Oncology
Quadruple-negative breast cancer associated with poorest outcomes
MDedge Hematology and Oncology
ER+/HER2− BC: ET+bevacizumab switch is an efficacious and safer alternative to paclitaxel
MDedge Hematology and Oncology
Invasive BC: Digital breast tomosynthesis+s2D mammography superior to digital mammography
MDedge Hematology and Oncology
HER2+/HR− BC: Responders to deescalated trastuzumab+pertuzumab can safely omit paclitaxel
MDedge Hematology and Oncology
HR+/HER2− metastatic BC: No survival benefit with palbociclib+ET over capecitabine in patients who progress on AI therapy
MDedge Hematology and Oncology
ER+ breast cancer: Ibandronate fails to improve DFS in TEAM-IIB trial
MDedge Hematology and Oncology
Risk for bilateral breast cancer among women with a history of LCIS
MDedge Hematology and Oncology